Revision history of "Secondline cabozantinib after sorafenib strategy for sophisticated hepatocellular carcinoma any subgroup research stage Three or more CELESTIAL trial"

From EECH Central
Jump to: navigation, search

Diff selection: Mark the radio boxes of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

  • (cur | prev) 09:32, 23 April 2024‎ Frenchswiss87 (Talk | contribs)‎ . . (3,775 bytes) (+3,775)‎ . . (Created page with "Constitutionnel along with business specifications associated with 310 divisions (cSCs 49.6%) had been removed. Median TTE price had been 63.3% (IQR Twenty [https://www.sellec...")
Retrieved from "http://eechcentral.simhq.com/index.php?title=Secondline_cabozantinib_after_sorafenib_strategy_for_sophisticated_hepatocellular_carcinoma_any_subgroup_research_stage_Three_or_more_CELESTIAL_trial"